Skip to content
MO

Altria Group, Inc.

Altria Group, Inc. Q1 FY2026 earnings call

April 30, 2026 · fiscal period ended 2026-03

EPS · actual vs est

$1.32 / $1.25Beat +5.6%

Revenue · actual vs est

$4.76B / $4.58BBeat +3.9%
Ask about this call

Summary

Generated 2026-04-30

Management highlights

Strong start to the year with adjusted diluted EPS up 7.3%. Highly cash generative businesses supported returns to shareholders. Smokable product segment income growth, marble in premium, PMUSA portfolio strategy. Orn and nicotine pouch performance, Helix's results and marketing efforts. eVapor category moderation due to enforcement and supply issues. Regulatory updates on ONPlus. Macroeconomic challenges affecting consumers, trade-down in cigarette segment. Investment in ABI, dividends and share repurchases.

View in transcript ↓

Segment performance

Smokable Product Segment: Generated strong income growth. Marble strengthened position in premium segment. PMUSA executed total portfolio strategy. Reported domestic cigarette volumes declined by 2.4%, but Marlboro expanded share in premium segment. BASIC captured share in discount segment. Cigars shipment volume down slightly, but Middleton outperformed. Oral Tobacco Product Segment: Delivered over $400 million in total adjusted OCI in Q1. Adjusted OCI margins 67.4%. Total segment reported shipment volume decreased 3.1%. Helix expanded portfolio in nicotine pouch category. Oil Tobacco Product Segment: Orn performed well, Helix expanded Orn Plus nationwide. Nicotine pouch category grew 9.1 share points, now over 58% of total oral tobacco.

View in transcript ↓

Guidance

Reaffirmed 2026 full year adjusted diluted EPS range of $5.56 to $5.72, growth 2.5%-5.5% from 2025. Strong Q1 performance leads to more balanced growth between first half and second half. Considers moderated evapor industry growth and macroeconomic uncertainty.

View in transcript ↓

Risks

Illicit flavored disposable products still prevalent, impacting eVapor category growth. Macro-economic challenges affecting consumer discretionary income, pressure on discount segment. Limited FDA authorized eVapor products constraining category progress. Regulatory uncertainties and enforcement effectiveness.

View in transcript ↓

Q&A highlights

Includes questions from various analysts about performance, smokable OCI, full year guidance, double duty drawback, Marlboro's cowboy cut, nicotine pouches, macro impact, eVapor strategy, shelf space for OnPlus, nicotine pouch strategy, BASIC's interaction with Marlboro, vape enforcement in Virginia. Answers from Altria executives addressing these points.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$1.32$1.25+5.6%
Revenue$4.76B$4.58B+3.9%

Transcript

April 30, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.